Daily Sepsis Research Analysis
Single-cell profiling of bronchoalveolar lavage fluid in sepsis delineates neutrophil-driven pulmonary immunosuppression and identifies five neutrophil subpopulations, prioritizing targets for intervention. A comprehensive meta-analysis shows host RNA biosignatures achieve good diagnostic accuracy for adult sepsis, including against SIRS comparators. Real-world, propensity-matched data suggest IVIG is associated with lower 28-day mortality and improved inflammatory/functional parameters in sepsi
Summary
Single-cell profiling of bronchoalveolar lavage fluid in sepsis delineates neutrophil-driven pulmonary immunosuppression and identifies five neutrophil subpopulations, prioritizing targets for intervention. A comprehensive meta-analysis shows host RNA biosignatures achieve good diagnostic accuracy for adult sepsis, including against SIRS comparators. Real-world, propensity-matched data suggest IVIG is associated with lower 28-day mortality and improved inflammatory/functional parameters in sepsis, informing the debate on adjunctive immunotherapy.
Research Themes
- Single-cell immunology and neutrophil heterogeneity in sepsis-induced pulmonary immunosuppression
- Transcriptomic diagnostics for early and accurate sepsis recognition
- Adjunctive immunotherapy (IVIG) and PICS mitigation in sepsis
Selected Articles
1. Single-Cell Landscape of Bronchoalveolar Lavage Fluid Identifies Specific Neutrophils during Septic Immunosuppression.
Single-cell RNA sequencing of BALF from patients with immunosuppressive sepsis delineated a neutrophil-driven immunosuppressive program in the lung. Immunosuppressive genes were upregulated across immune cells, yet only neutrophils expanded markedly in BALF during the immunosuppressive phase. Five neutrophil subpopulations were identified, highlighting neutrophil heterogeneity as a key determinant of pulmonary immune paralysis.
Impact: Provides a high-resolution atlas of pulmonary immune cells in sepsis and prioritizes neutrophil subsets as therapeutic targets for the immunosuppressive phase. This advances mechanistic understanding and opens avenues for precision immunomodulation.
Clinical Implications: Not practice-changing yet, but supports monitoring and potential targeting of specific neutrophil subsets (e.g., CXCR2-associated populations) to mitigate pulmonary immunosuppression and secondary infections.
Key Findings
- Single-cell RNA-seq of BALF mapped the immune landscape in immunosuppressive sepsis and revealed a neutrophil-driven immunosuppressive program.
- Immunosuppressive genes were upregulated across immune cells, but only neutrophils markedly increased in BALF during the immunosuppressive phase.
- Five distinct neutrophil subpopulations were identified in BALF of patients with immunosuppressive sepsis.
Methodological Strengths
- Patient-derived single-cell RNA sequencing providing cellular-resolution insights
- Direct profiling of bronchoalveolar compartments relevant to pulmonary sepsis
Limitations
- Sample size and patient demographics are not specified in the abstract
- Functional validation and longitudinal outcome correlations are not detailed
Future Directions: Validate neutrophil subpopulations across larger, multicenter cohorts; integrate functional assays and spatial profiling; test targeted modulation (e.g., chemokine receptor pathways) and link to clinical outcomes.
Sepsis-induced immunosuppression is related to increased susceptibility to secondary infections and death. Lung is the most vulnerable target organ in sepsis, but the understanding of the pulmonary immunosuppression state is still limited. Here, single-cell RNA sequencing of bronchoalveolar lavage fluid (BALF) is performed to map the landscape of immune cells, revealing a neutrophil-driven immunosuppressive program in the lungs of patients with immunosuppressive sepsis. Although immunosuppressive genes are upreg
2. The Diagnostic Utility of Host RNA Biosignatures in Adult Patients With Sepsis: A Systematic Review and Meta-Analysis.
Across 117 studies (n=17,469; 132 datasets), host RNA biosignatures achieved pooled AUC 0.86 (95% CI, 0.84–0.88) against combined controls. Diagnostic performance remained strong versus healthy controls (AUC 0.87) and against SIRS controls (AUC 0.84). Models with excellent discrimination against SIRS included UrSepsisModel (210 DEGs), microRNA-143, and Septicyte Lab.
Impact: Aggregates the global evidence base on transcriptomic diagnostics for adult sepsis, quantifying performance against clinically relevant comparators and guiding translational development.
Clinical Implications: Supports clinical evaluation of RNA-based diagnostics (e.g., Septicyte Lab) to accelerate early sepsis recognition and differentiation from SIRS, while underscoring the need for prospective validation and implementation studies.
Key Findings
- Pooled AUC for sepsis diagnosis using host RNA biosignatures was 0.86 (95% CI, 0.84–0.88) across 117 studies (n=17,469).
- Performance remained robust versus healthy controls (AUC 0.87) and SIRS controls (AUC 0.84).
- UrSepsisModel (210 DEGs), microRNA-143, and Septicyte Lab showed excellent discrimination against SIRS controls.
Methodological Strengths
- Comprehensive systematic review with random-effects meta-analysis across 132 datasets
- Diagnostic accuracy risk-of-bias assessment using QUADAS-2
Limitations
- Heterogeneity in study designs, platforms, and comparator groups (healthy vs SIRS)
- Limited prospective, real-world clinical validation and potential publication bias
Future Directions: Standardize biosignature panels and workflows; conduct prospective multicenter trials for clinical validation, utility, and cost-effectiveness in routine pathways.
OBJECTIVES: Sepsis is a life-threatening medical emergency, with a profound healthcare burden globally. Its pathophysiology is complex, heterogeneous and temporally dynamic, making diagnosis challenging. Medical management is predicated on early diagnosis and timely intervention. Transcriptomics is one of the novel "-omics" technologies being evaluated for recognition of sepsis. Our objective was to evaluate the performance of host gene expression biosignatures for the diagnosis of all-cause sepsis i
3. Intravenous immunoglobulin for mortality and inflammatory status in patients with sepsis: a retrospective database study.
In 15,159 eligible patients (758 IVIG recipients matched 1:1 to controls), 28-day mortality was lower with IVIG after propensity score matching: 11.9% vs 16.4% (risk difference -4.5% [95% CI, -8.0% to -1.0%]; P=0.015). In-hospital mortality was also lower (-5.3% absolute difference). Laboratory markers improved (higher albumin at days 14/28; lower CRP at day 28), and functional status at discharge was favored in the IVIG group.
Impact: Delivers contemporary, large-scale real-world evidence suggesting IVIG may reduce mortality and mitigate PICS-related abnormalities, informing patient selection and the design of definitive trials.
Clinical Implications: IVIG may be considered as an adjunct in selected sepsis patients while awaiting RCT confirmation, particularly where PICS features predominate; careful patient selection and monitoring remain essential.
Key Findings
- After propensity score matching (758 pairs), 28-day mortality was lower with IVIG (11.9%) vs control (16.4%); absolute risk difference -4.5% (P=0.015).
- In-hospital mortality decreased with IVIG by an absolute 5.3% in the matched cohort.
- Laboratory markers improved with IVIG: higher albumin on days 14 and 28, and lower CRP on day 28; functional status at discharge favored IVIG.
Methodological Strengths
- Large national claims database with propensity score matching to reduce confounding
- Assessment of mortality, laboratory, and functional outcomes including 28-day endpoints
Limitations
- Observational design with residual confounding and selection bias cannot establish causality
- Heterogeneity in IVIG dosing/timing and lack of granular severity/phenotype stratification
Future Directions: Conduct randomized trials enriched for PICS phenotypes; identify responsive subgroups and optimal dosing/timing; evaluate long-term functional recovery and cost-effectiveness.
BACKGROUND: Sepsis is a life-threatening condition caused by severe infection. The efficacy of intravenous immunoglobulin (IVIG) as adjunctive therapy on mortality remains controversial. Moreover, IVIG may favorably affect sepsis-induced immunosuppression like persistent inflammation, immunosuppression, and catabolism syndrome (PICS). METHODS: This study was a retrospective cohort study using inpatient claims database provided by Medical Data Vision, which included approximately 190,000 episodes of in